RecruitingPhase 2Drug trialPhase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant LesionsTo evaluate the antitumor efficacy of intralesional injections of nivolumab in patients with high-risk oral premalignant lesions